Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca
| dc.rights.license | open | en_US |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | OLIVEIRA DA CRUZ, Jose F. | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | IOANNIDOU, Christina | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | PAGANO ZOTTOLA, Antonio C. | |
| dc.contributor.author | MUGURUZA, Carolina | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | GOMEZ-SOTRES, Paula | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | FERNANDEZ, Monica | |
| dc.contributor.author | CALLADO, Luis F. | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | MARSICANO, Giovanni | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | BUSQUETS-GARCIA, Arnau | |
| dc.date.accessioned | 2022-03-07T14:27:33Z | |
| dc.date.available | 2022-03-07T14:27:33Z | |
| dc.date.issued | 2021-05 | |
| dc.identifier.issn | 1369-1600 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/129933 | |
| dc.description.abstractEn | Synthetic cannabinoids have emerged as novel psychoactive substances with damaging consequences for public health. They exhibit high affinity at the cannabinoid type-1 (CB1) receptor and produce similar and often more potent effects as other CB1 receptor agonists. However, we are still far from a complete pharmacological understanding of these compounds. In this study, by using behavioral, molecular, pharmacological, and electrophysiological approaches, we aimed at characterizing several in vitro and in vivo pharmacological effects of the synthetic cannabinoid MMB-Fubinaca (also known as AMB-Fubinaca or FUB-AMB), a particular synthetic cannabinoid. MMB-Fubinaca stimulates CB1 receptor-mediated functional coupling to G-proteins in mouse and human brain preparations in a similar manner as the CB1 receptor agonist WIN55,512-2 but with a much greater potency. Both drugs similarly activate the CB1 receptor-dependent extracellular signal-regulated kinase (ERK) pathway. Notably, in vivo administration of MMB-Fubinaca in mice induced greater behavioral and electrophysiological effects in male than in female mice in a CB1 receptor-dependent manner. Overall, these data provide a solid pharmacological profiling of the effects of MMB-Fubinaca and important information about the mechanisms of action underlying its harmful impact in humans. At the same time, they reinforce the significant sexual dimorphism of cannabinoid actions, which will have to be taken into account in future animal and clinical studies. | |
| dc.description.sponsorship | Représentation sensorielle lors d'états psychotiques - ANR-16-CE37-0010 | en_US |
| dc.description.sponsorship | Bordeaux Region Aquitaine Initiative for Neuroscience - ANR-10-LABX-0043 | en_US |
| dc.description.sponsorship | Initiative d'excellence de l'Université de Bordeaux | en_US |
| dc.language.iso | EN | en_US |
| dc.subject.en | AMB-Fubinaca | |
| dc.subject.en | FUB-AMB | |
| dc.subject.en | MMB-Fubinaca | |
| dc.title.en | Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca | |
| dc.title.alternative | Addict Biol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/adb.12940 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 32744799 | en_US |
| dc.description.sponsorshipEurope | Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for thetreatment of schizophrenia and psychotic syndromes | en_US |
| bordeaux.journal | Addiction Biology | en_US |
| bordeaux.volume | 26 | en_US |
| bordeaux.hal.laboratories | Neurocentre Magendie - UMR-S 1215 | en_US |
| bordeaux.issue | 3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut National de la Santé et de la Recherche Médicale | en_US |
| hal.identifier | hal-03600431 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-03-07T14:27:36Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Addiction%20Biology&rft.date=2021-05&rft.volume=26&rft.issue=3&rft.eissn=1369-1600&rft.issn=1369-1600&rft.au=OLIVEIRA%20DA%20CRUZ,%20Jose%20F.&IOANNIDOU,%20Christina&PAGANO%20ZOTTOLA,%20Antonio%20C.&MUGURUZA,%20Carolina&GOMEZ-SOTRES,%20Paula&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||